Intranasal Therapeutics for Alzheimer's Disease

Abstract

Alzheimer's disease (AD) is an age-related, irreversible, and progressive neurodegenerative disorder that accounts for 70% of all dementia cases worldwide, with approximately 35 million individuals affected. The neurodegenerative effects caused by AD are among the leading causes of disability and mortality in the elderly population. Current treatment strategies for AD are limited and primarily rely on approaches such as cholinergic replacement therapy and the inhibition of glutamate excitotoxicity. However, these treatments provide only symptomatic relief and are insufficient in halting disease progression. This limitation has increased interest in the potential role of neuroprotective drugs in the management of AD. Recently, the direct intranasal delivery of drugs to the central nervous system (CNS) has emerged as a therapeutically viable alternative to oral and parenteral administration methods. This review focuses on the potential efficacy of neuroprotective therapies in AD models. Additionally, it aims to discuss the mechanisms of intranasal drug delivery to the CNS and its role in the management of AD. In light of recent findings, the review seeks to contribute to advancements in this field by summarizing key studies on intranasal drug delivery.

Cite this article as: İlhan AB, Erbaş O. Intranasal Therapeutics for Alzheimer's Disease. JEB Med Sci 2024;5(4):241-246.

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

The authors received no financial support for the research and/or authorship of this article.